Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. whilyas

WHILYAS

Wound healing ILYA-style

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 WHILYAS project word cloud

Explore the words cloud of the WHILYAS project. It provides you a very rough idea of what is the project "WHILYAS" about.

limb    lactobacillus    heal    healthcare    acid    cagr    dressings    ulcers    ev100    unmet    15    healed    total    designed    faster    implying    world    drugs    wound    regeneration    million    industrialized    genetically    budget    complications    ilya100tm    efficiency    annual    immunophysiology    chronic    local    countries    2014    water    patients    proteins    library    bioreactors    group    30    microbiology    11    accelerate    market    least    freeze    drug    18    dried    billion    eur    diabetes    agricultural    cancers    amputation    first    possibly    chemokine    approx    human    innovation    wounds    alone    personal    care    sciences    2011    people    diabetic    swedish    chosen    administration    translates    prior    uppsala    4    tackling    cxcl12    small    66    bacteria    alarming    lactic    savings    site    healing    quality    endogenously    debridement    cheaper    act    difficulties    therapeutic    tissue    mortality    life    medical    rate    stems    expressing    revived    topical    dfus    substantial    university    overuse    delivered    modified    social    segment    foot    candidate    limited    manner    treatment    antibiotics    spend    mechanical   

Project "WHILYAS" data sheet

The following table provides information about the project.

Coordinator		 ILYA PHARMA AB 

Organization address
address: DAG HAMMARSKIOLDS VAG 30
city: UPPSALA
postcode: 752 37
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Sweden [SE]
 Project website http://www.ilyapharma.se
 Total cost 2˙992˙575 €
 EC max contribution 2˙992˙575 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-03-01   to  2019-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ILYA PHARMA AB SE (UPPSALA) coordinator 2˙992˙575.00

Map

 Project objective

The objective of the project is to develop the EV100 drug candidate to heal chronic wounds in patients with diabetes in a better, faster, and cheaper manner than any method available today. We have chosen to target wounds in patients with diabetes, due to a large unmet medical need in this group. Today, 18% of people with diabetes have a chronic wound which translates into at least 6 million people in Europe alone. One of the complications of diabetes, diabetic foot ulcers (DFUs) often result in limb amputation. The mortality rate after an amputation is 30% within the first year, which is similar to several cancers. Even more alarming, treatment is today limited to mechanical debridement, use of different dressings, and a substantial overuse of antibiotics. Industrialized countries spend 2-4% of total healthcare budget on chronic wounds. The market for wound care is EUR 15 billion and the segment of DFUs is in the range of EUR 1.5 billion, with 11% CAGR 2011-2014. We have designed and built genetically modified lactic acid bacteria that accelerate wound healing with a unique efficiency. Human therapeutic proteins endogenously involved in tissue regeneration are continuously delivered on site in wounds by the lactic acid bacteria that act like small local bioreactors. EV100 is one of the candidate drugs in our library using Ilya100TM technology and is Lactobacillus expressing the human chemokine CXCL12. The Lactobacillus are freeze-dried and revived with water just prior to topical administration. The innovation stems from world-leading medical research in immunophysiology and microbiology at Uppsala University and the Swedish University of Agricultural Sciences. With EV100 chronic wounds could possibly be healed approx. 66% faster, implying annual cost savings of EUR 6 billion in the US and Europe and tackling all the personal and social difficulties associated with chronic wounds, increasing the quality of life of patients all around the world.

 Deliverables

List of deliverables.
An updated plan for the exploitation and dissemination of the results Documents, reports 2020-02-11 12:59:43
ORDP - Open Research Data Pilot Open Research Data Pilot 2020-02-11 12:59:43

Take a look to the deliverables list in detail:  detailed list of WHILYAS deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 Evelina Vågesjö, Emelie Öhnstedt, Anneleen Mortier, Hava Lofton, Fredrik Huss, Paul Proost, Stefan Roos, Mia Phillipson
Accelerated wound healing in mice by on-site production and delivery of CXCL12 by transformed lactic acid bacteria
published pages: 1895-1900, ISSN: 0027-8424, DOI: 10.1073/pnas.1716580115 		Proceedings of the National Academy of Sciences 115/8 2020-02-11
2019 Emelie Öhnstedt, Hava Lofton Tomenius, Evelina Vågesjö, Mia Phillipson
The discovery and development of topical medicines forwound healing
published pages: , ISSN: 1746-045X, DOI: 		Expert Opinion on Drug Discovery 2020-02-11

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "WHILYAS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "WHILYAS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More